Findings challenge prevailing ignition–sustainment assumptions, reframing plasma instability as a systems-level ...

We designed the platform so business leaders and their teams can think clearly, act decisively, and stay accountable ...

From football fields to military training grounds, head injuries are leaving lasting marks on the brain in ways we're only beginning to understand. Repeated concussions can increase the risk of mood ...

COVID-19-associated thrombotic microangiopathy has emerged as a severe complication that exacerbates morbidity and mortality in critical cases. Thrombotic microangiopathy, characterized by ...

Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...

FDA approval enables Complement Therapeutics to start the Opti-GAIN phase 1/2 trial for CTx001 in GA secondary to AMD. CTx001 is an AAV-based gene therapy delivering a truncated Complement Receptor 1 ...

Aptamer Group plc, a developer of next-generation synthetic binders for the life sciences industry, has signed a new therapeutic development agreement with Invizius, a clinical-stage biotechnology ...

The story of Q32 Bio, a company that develops therapeutics for inflammatory and autoimmune diseases, started two decades ago. That's when V. Michael Holers, MD, a University of Colorado School of ...

Scientists at the University of Pennsylvania have uncovered the mathematical rules that govern one of the body’s oldest and most important immune system defenses, the complement system, according to ...

Kawasaki Disease (KD) is an acute febrile systemic vasculitis of unknown etiology and the leading cause of acquired heart disease among children. The complement system is a major component of innate ...